Hepatocellular Carcinoma News and Research RSS Feed - Hepatocellular Carcinoma News and Research

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights. [More]
Researchers develop novel strategy in fight against cancer

Researchers develop novel strategy in fight against cancer

A team of researchers led by Associate Professor Caroline Lee from the Yong Loo Lin School of Medicine at the National University of Singapore, in collaboration with Associate Professor Song Jianxing of the Department of Biological Sciences at the NUS Faculty of Science, has developed a novel strategy in the fight against cancer. [More]
Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). [More]
Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer. [More]
Age and HBsAg level predict NA-induced HBeAg seroconversion durability

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report. [More]
Using breath tests to diagnose liver diseases: an interview with Larry Cohen

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

It was back in the 1960s that scientists first started to understand that breath could be used to find out different things about diseases and other factors. I’m sure you’re familiar with alcohol breath testing, which was patented back in the ‘50s and has been used since the ‘60s. [More]
Researchers examine how terpenes can inhibit growth of liver cancer cells

Researchers examine how terpenes can inhibit growth of liver cancer cells

As main component of essential oils, terpenes can inhibit the growth of different cancer cells. Researchers from the Ruhr-University Bochum headed by Prof Dr Dr Dr Hanns Hatt have analysed this process in liver cancer cells in detail. [More]
GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). [More]
Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. [More]
Study underscores the importance of appropriate testing, support and care for HCV patients

Study underscores the importance of appropriate testing, support and care for HCV patients

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. [More]
Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
New study highlights importance of generating awareness about HCV testing, support and care

New study highlights importance of generating awareness about HCV testing, support and care

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care. [More]
Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. [More]
Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma. [More]
Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over recent years. Globally, there are approximately 750,000 new cases of liver cancer reported each year. Importantly, population-based studies show that HCC ranks as the third leading cause of cancer-related deaths worldwide. [More]
CARsgen announces completion of series A financing

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Unique immunochemotherapy approach to treating pancreatic cancer

Unique immunochemotherapy approach to treating pancreatic cancer

VCU Massey Cancer Center and VCU Institute of Molecular Medicine researchers discovered a unique approach to treating pancreatic cancer that may be potentially safe and effective. The treatment method involves immunochemotherapy - a combination of chemotherapy and immunotherapy, which uses the patient's own immune system to help fight against disease. [More]
Study examines overall survival of patients with chronic HCV infection, cirrhosis

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA. [More]